New Triple-Hormone Drug Combo Drives 23% Weight Loss in Type 2 Diabetes Trial
Eloralintide plus tirzepatide achieved 23.3% body weight loss in 48 weeks — surpassing bariatric surgery benchmarks — but tolerability remains a serious hurdle.
Summary
A phase IIb trial presented at the EASD annual meeting found that combining eloralintide, a selective amylin receptor agonist, with tirzepatide produced 23.3% body weight loss over 48 weeks in adults with type 2 diabetes — more than tirzepatide alone (14.8%) and even more than tirzepatide achieves in people without diabetes. One quarter of participants in the highest-dose group lost at least 30% of their body weight, a threshold comparable to metabolic surgery. Nearly all participants also achieved HbA1c below 7%, with 77% reaching normoglycemia. However, 27% of participants in the highest-dose combination arm discontinued due to adverse events, compared with just 2.9% on tirzepatide alone, raising important questions about tolerability and long-term viability.
Detailed Summary
Obesity and type 2 diabetes are deeply intertwined cardiometabolic conditions that dramatically accelerate aging and shorten healthspan. New pharmacological strategies that can address both simultaneously represent a significant advance in metabolic medicine. A phase IIb trial presented at the European Association for the Study of Diabetes meeting in Milan tested an investigational combination of eloralintide plus tirzepatide in 367 adults with obesity or overweight and type 2 diabetes.
The headline result: participants on the highest dose of the combination lost 23.3% of their body weight over 48 weeks, compared with 14.8% for those receiving tirzepatide alone. This is remarkable because people with type 2 diabetes historically lose less weight on GLP-1-based therapies than those without the condition. The combination drug even outperformed tirzepatide's results in non-diabetic populations, where it achieves roughly 20.9% weight loss.
The glycemic results were equally striking. Ninety-six percent of participants in the highest-dose combination group achieved an HbA1c below 7% — the standard clinical target — and 77% reached normoglycemia (HbA1c below 5.7%), versus 66% on tirzepatide alone. A quarter of patients in the combination arm lost at least 30% of body weight, a benchmark previously associated only with bariatric surgery.
The mechanism behind these results involves simultaneously activating three complementary nutrient-stimulated hormonal pathways — GIP, GLP-1, and amylin — while minimizing calcitonin receptor activity. Eloralintide is a selective amylin receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. Targeting multiple hormonal axes appears to produce synergistic effects on hunger, blood sugar, and body composition.
However, tolerability is a significant concern. Around 84% of participants on the highest-dose combination experienced treatment-emergent adverse events, and 27% discontinued due to adverse events — nearly ten times the dropout rate of the tirzepatide-alone group (2.9%). These safety signals will need to be carefully characterized in larger, longer trials before this combination could enter routine clinical use.
Key Findings
- Eloralintide plus tirzepatide produced 23.3% weight loss in 48 weeks vs 14.8% with tirzepatide alone in type 2 diabetes patients.
- 25% of highest-dose combination participants lost 30%+ body weight, matching bariatric surgery benchmarks.
- 96% of combination-group participants reached the standard HbA1c target of below 7%; 77% achieved normoglycemia.
- Triple-hormone pathway targeting (GIP, GLP-1, amylin) appears to drive greater metabolic benefit than dual-agonist therapy alone.
- 27% of highest-dose combination participants discontinued due to adverse events vs 2.9% on tirzepatide alone — a major tolerability gap.
Methodology
This is a conference news report covering a phase IIb randomized, double-blind, parallel-group trial (n=367) presented at the EASD 2026 annual meeting. MedPage Today is a credible physician-facing medical news outlet. The full peer-reviewed publication has not yet been cited, so precise statistical details and safety data should be verified against the primary publication.
Study Limitations
Data are from a conference presentation; the peer-reviewed paper has not been cited, so methodology and full safety profiles need independent verification. The 48-week trial duration does not yet reveal long-term weight maintenance, cardiovascular outcomes, or safety signals that may emerge over years. Dropout rates of 27% in the highest-dose arm may bias efficacy estimates upward via the efficacy estimand analysis used.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: